Open House Originale Rabattverträge 2025-05 - Emtricitabin/tenofovirdisoproxil/rilpivirin (wirkstoffkombination)

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

February 27, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)

This Germany Health Services opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryHealth Services
PublishedJanuary 21, 2025
Procurement stageActive solicitation
Response dueFebruary 27, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion)
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-35 - Natalizumab (Darreichungsform zur intravenösen Anwendung)
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-10
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-15
Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-08
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten)
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion)
Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-11

See every Germany Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Health Services intelligence report in your inbox

A personalized report on Germany Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.